Cell culture-based influenza vaccines as alternatives to egg-based vaccines

Journal of Bacteriology and Virology

Volumn 43, Issue 1, 2013, Pages 9-17

  Lee, Ilseob ^a   Kim, Jin Il ^a   Park, Man Seong ^a  

^a Hallym University   (South Korea)

Author keywords

Egg; Influenza; MDCK; Vaccine; Vero

Indexed keywords

CELL CULTURE BASED INFLUENZA VACCINE; EGG BASED INFLUENZA VACCINE; INFLUENZA VACCINE; UNCLASSIFIED DRUG; VIRUS VACCINE;

CULTURE TECHNIQUE; DRUG EFFICACY; EGG PRODUCTION; IMMUNOGENICITY; INFLUENZA VIRUS; MDCK CELL LINE; PANDEMIC INFLUENZA; PER C6 CELL LINE; REVIEW; VACCINE PRODUCTION; VERO CELL LINE;

EID: 84922687007     PISSN: 15982467     EISSN: None     Source Type: Journal    
DOI: 10.4167/jbv.2013.43.1.9     Document Type: Review

References (63)

1. Lee I, Kim JI, Park MS. A Novel PA-X Protein Translated from Influenza A Virus Segment 3. J Bacteriol Virol 2012;42: 368-71.
2. Tong S, Li Y, Rivailler P, Conrardy C, Castillo DA, Chen LM, et al. A distinct lineage of influenza A virus from bats. Proc Natl Acad Sci U S A 2012;109:4269-74.
3. WHO. Fact sheet on influenza. 2009.
4. Klenk HD, Garten W, Matrosovich M. Molecular mechanisms of interspecies transmission and pathogenicity of influenza viruses: Lessons from the 2009 pandemic. Bioessays 2011;33: 180-8.
5. WHO. Cumulative number of confirmed human cases of avian influenza A (H5N1) reported to WHO. 2012.
6. Park S, Kim JI, Park MS. Antiviral Agents Against Influenza Viruses. J Bacteriol Virol 2012;42:284-93.
7. Cox NJ, Subbarao K. Influenza. Lancet 1999;354:1277-82.
8. Kim JI, Park MS. An Universal Approach to Getting Ahead for Influenza B Vaccines. J Bacteriol Virol 2012;42:363-7.
9. Traynor K. First quadrivalent flu vaccine approved. Am J Health Syst Pharm 2012;69:538.
10. WHO. A description of the process of seasonal and H5N1 influenza vaccine virus selection and development. 2007.
11. Nicholson KG WR, Hay AJ. Textbook of Influenza. Oxford: Blackwell Science Ltd., 1998.
12. WHO. Cell culture as a substrate for the production of influenza vaccines: memorandum from a WHO meeting. Bull World Health Organ 1995;73:431-5.
13. Magrath DI. Safety of vaccines produced in continuous cell lines. Dev Biol Stand 1991;75:17-20.
14. Merten OW, Hannoun C, Manuguerra JC, Ventre F, Petres S. Production of influenza virus in cell cultures for vaccine preparation. Adv Exp Med Biol 1996;397:141-51.
15. Tannock GA, Bryce DA, Paul JA. Evaluation of chicken kidney and chicken embryo kidney cultures for the large-scale growth of attenuated influenza virus master strain A/Ann/ Arbor/6/60-ca. Vaccine 1985;3:333-9.
16. Kistner O, Barrett PN, Mundt W, Reiter M, Schober-Bendixen S, Dorner F. Development of a mammalian cell (Vero) derived candidate influenza virus vaccine. Vaccine 1998;16:960-8.
17. PATH. Influenza Vaccine Strategies for Broad Global Access. www.oliverwyman.com/media/VAC_infl_publ_rpt_10-07.pdf. 2007.
18. Feng SZ, Jiao PR, Qi WB, Fan HY, Liao M. Development and strategies of cell-culture technology for influenza vaccine. Appl Microbiol Biotechnol 2011;89:893-902.
19. Gerdil C. The annual production cycle for influenza vaccine. Vaccine 2003;21:1776-9.
20. WHO. World now at the start of 2009 influenza pandemic. 2009.
21. Pandey A, Singh N, Sambhara S, Mittal SK. Egg-independent vaccine strategies for highly pathogenic H5N1 influenza viruses. Hum Vaccin 2010;6:178-88.
22. Robertson JS, Naeve CW, Webster RG, Bootman JS, Newman R, Schild GC. Alterations in the hemagglutinin associated with adaptation of influenza B virus to growth in eggs. Virology 1985;143:166-74.
23. Oxford JS, Schild GC, Corcoran T, Newman R, Major D, Robertson J, et al. A host-cell-selected variant of influenza B virus with a single nucleotide substitution in HA affecting a potential glycosylation site was attenuated in virulence for volunteers. Arch Virol 1990;110:37-46.
24. Oxford JS, Corcoran T, Knott R, Bates J, Bartolomei O, Major D, et al. Serological studies with influenza A(H1N1) viruses cultivated in eggs or in a canine kidney cell line (MDCK). Bull World Health Organ 1987;65:181-7.
25. Katz JM, Webster, RG. Amino acid sequence identity between the HA1 of influenza A (H3N2) viruses grown in mammalian and primary chick kidney cells. J Gen Virol 1992;73:1159-65.
26. Katz JM, Wang M, Webster RG. Direct sequencing of the HA gene of influenza (H3N2) virus in original clinical samples reveals sequence identity with mammalian cell-grown virus. J Virol 1990;64:1808-11.
27. James JM, Zeiger RS, Lester MR, Fasano MB, Gern JE, Mansfield LE, et al. Safe administration of influenza vaccine to patients with egg allergy. J Pediatr 1998;133:624-8.
28. WHO. Use of Cell Lines for the Production of Influenza Virus Vaccines: An Appraisal of Technical, Manufacturing, and Regulatory Considerations. 2007.
29. Barrett PN, Mundt W, Kistner O, Howard MK. Vero cell platform in vaccine production: moving towards cell culturebased viral vaccines. Expert Rev Vaccines 2009;8:607-18.
30. U.S. Health and Human Services. HHS Awards Contracts Totaling More Than $1 Billion To Develop Cell-Based Influenza Vaccine. 2006.
31. U.S. Health and Human Services. HHS Awards $487 Million Contract to Build First U.S. Manufacturing Facility for Cell-Based Influenza Vaccine. 2009.
32. Montagnon BJ, Fanget B, Nicolas AJ. The large-scale cultivation of VERO cells in micro-carrier culture for virus vaccine production. Preliminary results for killed poliovirus vaccine. Dev Biol Stand 1981;47:55-64.
33. SanofiPasteur. Our vaccines: a history of innovation. www.sanofipasteur.com/index.jsp?codeRubrique=14&lang= EN.
34. Montagnon BJ. Polio and rabies vaccines produced in continuous cell lines: a reality for Vero cell line. Dev Biol Stand 1989;70:27-47.
35. Schuller E, Jilma B, Voicu V, Golor G, Kollaritsch H, Kaltenböck A, et al. Long-term immunogenicity of the new Vero cell-derived, inactivated Japanese encephalitis virus vaccine IC51 Six and 12 month results of a multicenter follow-up phase 3 study. Vaccine 2008;26:4382-6.
36. Tauber E, Kollaritsch H, von Sonnenburg F, Lademann M, Jilma B, Firbas C, et al. Randomized, double-blind, placebocontrolled phase 3 trial of the safety and tolerability of IC51, an inactivated Japanese encephalitis vaccine. J Infect Dis 2008; 198:493-9.
37. Tauber E, Kollaritsch H, Korinek M, Rendi-Wagner P, Jilma B, Firbas C, et al. Safety and immunogenicity of a Vero-cellderived, inactivated Japanese encephalitis vaccine: a noninferiority, phase III, randomised controlled trial. Lancet 2007; 370:1847-53.
38. Lyons A, Kanesa-thasan N, Kuschner RA, Eckels KH, Putnak R, Sun W, et al. A Phase 2 study of a purified, inactivated virus vaccine to prevent Japanese encephalitis. Vaccine 2007; 25:3445-53.
39. Dennehy PH. Rotavirus vaccines: an overview. Clin Microbiol Rev 2008;21:198-208.
40. Lau SC, Scholtissek C. Abortive infection of Vero cells by an influenza A virus (FPV). Virology 1995;212:225-31.
41. Nakamura K, Homma M. Protein synthesis in Vero cells abortively infected with influenza B virus. J Gen Virol 1981; 56:199-202.
42. Govorkova EA, Kaverin NV, Gubareva LV, Meignier B, Webster RG. Replication of influenza A viruses in a green monkey kidney continuous cell line (Vero). J Infect Dis 1995; 172:250-3.
43. Kaverin NV, Webster RG. Impairment of multicycle influenza virus growth in Vero (WHO) cells by loss of trypsin activity. J Virol 1995;69:2700-3.
44. Govorkova EA, Murti G, Meignier B, de Taisne C, Webster RG. African green monkey kidney (Vero) cells provide an alternative host cell system for influenza A and B viruses. J Virol 1996;70:5519-24.
45. Baxter. Baxter Receives European Commission Approval for CELVAPAN H1N1 Pandemic Influenza Vaccine. 2009.
46. Baxter. Baxter Receives EMEA Positive Opinion for CELVAPAN, the First Cell Culture-based Pandemic Flu Vaccine. 2008.
47. Minor PD, Engelhardt OG, Wood JM, Robertson JS, Blayer S, Colegate T, et al. Current challenges in implementing cellderived influenza vaccines: implications for production and regulation, July 2007, NIBSC, Potters Bar, UK. Vaccine 2009; 27:2907-13.
48. Tree JA, Richardson C, Fooks AR, Clegg JC, Looby D. Comparison of large-scale mammalian cell culture systems with egg culture for the production of influenza virus A vaccine strains. Vaccine 2001;19:3444-50.
49. Liu J, Shi X, Schwartz R, Kemble G. Use of MDCK cells for production of live attenuated influenza vaccine. Vaccine 2009; 27:6460-3.
50. Genzel Y, Reichl U. Continuous cell lines as a production system for influenza vaccines. Expert Rev Vaccines 2009;8: 1681-92.
51. Liu J, Mani S, Schwartz R, Richman L, Tabor DE. Cloning and assessment of tumorigenicity and oncogenicity of a Madin-Darby canine kidney (MDCK) cell line for influenza vaccine production. Vaccine 2010;28:1285-93.
52. Novartis. Novartis receives FDA approval for Flucelvax®, the first cell-culture vaccine in US to help protect against seasonal influenza. 2012.
53. Pau MG, Ophorst C, Koldijk MH, Schouten G, Mehtali M, Uytdehaag F. The human cell line PER. C6 provides a new manufacturing system for the production of influenza vaccines. Vaccine 2001;19:2716-21.
54. Cox RJ, Madhun AS, Hauge S, Sjursen H, Major D, Kuhne M, et al. A phase I clinical trial of a PER. C6 cell grown influenza H7 virus vaccine. Vaccine 2009;27:1889-97.
55. Ledwith BJ, Lanning CL, Gumprecht LA, Anderson CA, Coleman JB, Gatto NT, et al. Tumorigenicity assessments of Per. C6 cells and of an Ad5-vectored HIV-1 vaccine produced on this continuous cell line. Dev Biol (Basel) 2006;123:251-63.
56. Zhang W, Xue T, Wu X, Zhang P, Zhao G, Peng D, et al. Increase in viral yield in eggs and MDCK cells of reassortant H5N1 vaccine candidate viruses caused by insertion of 38 amino acids into the NA stalk. Vaccine 2011;29:8032-41.
57. Tseng YF, Hu AY, Huang ML, Yeh WZ, Weng TC, Chen YS, et al. Adaptation of high-growth influenza H5N1 vaccine virus in Vero cells: implications for pandemic preparedness. PLoS One 2011;6:e24057.
58. Murakami S, Horimoto T, Ito M, Takano R, Katsura H, Shimojima M, et al. Enhanced growth of influenza vaccine seed viruses in vero cells mediated by broadening the optimal pH range for virus membrane fusion. J Virol 2012;86:1405-10.
59. Szymczakiewicz-Multanowska A, Groth N, Bugarini R, Lattanzi M, Casula D, Hilbert A, et al. Safety and immunogenicity of a novel influenza subunit vaccine produced in mammalian cell culture. J Infect Dis 2009;200:841-8.
60. Reisinger KS, Block SL, Izu A, Groth N, Holmes SJ. Subunit influenza vaccines produced from cell culture or in embryonated chicken eggs: comparison of safety, reactogenicity, and immunogenicity. J Infect Dis 2009;200:849-57.
61. Groth N, Montomoli E, Gentile C, Manini I, Bugarini R, Podda A. Safety, tolerability and immunogenicity of a mammalian cell-culture-derived influenza vaccine: a sequential Phase I and Phase II clinical trial. Vaccine 2009;27:786-91.
62. Hatz C, Cramer JP, Vertruyen A, Schwarz TF, von Sonnenburg F, Borkowski A, et al. A randomised, single-blind, dose-range study to assess the immunogenicity and safety of a cellculture-derived A/H1N1 influenza vaccine in adult and elderly populations. Vaccine 2012;30:4820-7.
63. Ehrlich HJ, Müller M, Oh HM, Tambyah PA, Joukhadar C, Montomoli E, et al. A clinical trial of a whole-virus H5N1 vaccine derived from cell culture. N Engl J Med 2008;358: 2573-84.